MCID: RTN018
MIFTS: 58

Retinal Disease

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Disease

Summaries for Retinal Disease

MedlinePlus : 44 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. In the center of this nerve tissue is the macula. It provides the sharp, central vision needed for reading, driving and seeing fine detail. Retinal disorders affect this vital tissue. They can affect your vision, and some can be serious enough to cause blindness. Examples are Macular degeneration - a disease that destroys your sharp, central vision Diabetic eye disease Retinal detachment - a medical emergency, when the retina is pulled away from the back of the eye Retinoblastoma - cancer of the retina. It is most common in young children. Macular pucker - scar tissue on the macula Macular hole - a small break in the macula that usually happens to people over 60 Floaters - cobwebs or specks in your field of vision NIH: National Eye Institute

MalaCards based summary : Retinal Disease, also known as retinal diseases, is related to macular dystrophy, vitelliform, 3 and cone-rod dystrophy, x-linked, 3, and has symptoms including eye manifestations An important gene associated with Retinal Disease is PRPH2 (Peripherin 2), and among its related pathways/superpathways are Phototransduction and Visual Cycle in Retinal Rods. The drugs Acarbose and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are nervous system and pigmentation

Disease Ontology : 12 An eye disease that is located in the retina.

Wikipedia : 77 The retina is the innermost, light-sensitive layer of tissue of the eye of most vertebrates and some... more...

Related Diseases for Retinal Disease

Diseases related to Retinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 macular dystrophy, vitelliform, 3 31.8 BEST1 PRPH2
2 cone-rod dystrophy, x-linked, 3 31.8 CACNA1F RPGR
3 oguchi disease 31.7 CACNA1F PDE6B RHO
4 stargardt disease 1 31.7 ABCA4 CRX RHO
5 enhanced s-cone syndrome 31.7 AIPL1 CRX NR2E3
6 cone dystrophy 31.7 BEST1 RHO RPGR
7 prolonged electroretinal response suppression 31.6 ABCA4 CRB1 CRX GUCY2D PRPH2
8 congenital stationary night blindness 31.5 ABCA4 AIPL1 CACNA1F PDE6B RHO RPE65
9 stargardt disease 31.4 ABCA4 CRB1 MYO7A PRPH2 RHO RPE65
10 retinal degeneration 31.2 ABCA4 AIPL1 BEST1 CRB1 CRX GUCY2D
11 leber congenital amaurosis 31.0 ABCA4 AIPL1 BEST1 CEP290 CRB1 CRX
12 retinitis 30.9 PRPH2 RHO RPGR
13 usher syndrome, type i 30.8 MYO7A RHO USH2A
14 severe early-childhood-onset retinal dystrophy 30.6 ABCA4 RPE65
15 macular dystrophy, concentric annular 30.5 ABCA4 CRX
16 leber congenital amaurosis 12 30.5 CEP290 GUCY2D RPE65
17 retinitis pigmentosa 19 30.5 ABCA4 PDE6B RHO
18 peripheral retinal degeneration 30.5 BEST1 PRPH2 RPGR
19 central serous chorioretinopathy 30.5 ARMS2 CFH
20 leber congenital amaurosis 10 30.5 CEP290 RPE65
21 usher syndrome, type iid 30.4 MYO7A RHO RPGR USH2A
22 retinitis pigmentosa-deafness syndrome 30.4 MYO7A USH2A
23 retinitis pigmentosa 50 30.4 BEST1 RPGR
24 retinitis pigmentosa 13 30.4 PRPF31 RPGR
25 leber congenital amaurosis 4 30.4 AIPL1 CRX GUCY2D RPE65
26 hereditary retinal dystrophy 30.4 CEP290 GUCY2D RHO RS1
27 usher syndrome, type iic 30.4 CRB1 MYO7A PDE6B USH2A
28 fundus albipunctatus 30.4 CACNA1F PDE6B PRPH2 RHO RPE65
29 retinitis pigmentosa 43 30.4 PDE6B RHO
30 macular dystrophy, dominant cystoid 30.4 BEST1 CRB1
31 leber congenital amaurosis 9 30.3 AIPL1 CRB1 CRX GUCY2D RPE65
32 degeneration of macula and posterior pole 30.3 ABCA4 ARMS2 CFH RHO RPE65
33 usher syndrome, type id 30.3 MYO7A USH2A
34 macular degeneration, age-related, 1 30.1 ABCA4 ARMS2 BEST1 CFH CRB1 PRPH2
35 choroiditis 30.0 ARMS2 CFH
36 achromatopsia 30.0 CACNA1F NR2E3 RPE65 RPGR
37 cone-rod dystrophy 2 30.0 ABCA4 AIPL1 CRX GUCY2D NR2E3 PRPH2
38 coats disease 29.9 CRB1 RHO RS1
39 macular retinal edema 29.5 BEST1 CRB1
40 yemenite deaf-blind hypopigmentation syndrome 29.3 ABCA4 AIPL1 CEP290 CFH CRB1 GUCY2D
41 retinitis pigmentosa 28.8 ABCA4 AIPL1 BEST1 CACNA1F CEP290 CRB1
42 jalili syndrome 11.0
43 usher syndrome, type iia 10.9
44 aland island eye disease 10.9
45 night blindness, congenital stationary, type 1a 10.8
46 night blindness, congenital stationary, type 1e 10.8
47 night blindness, congenital stationary, type 1h 10.8
48 vitreoretinochoroidopathy 10.7
49 choroidal dystrophy, central areolar, 1 10.7
50 choroidal dystrophy, central areolar 2 10.7

Graphical network of the top 20 diseases related to Retinal Disease:



Diseases related to Retinal Disease

Symptoms & Phenotypes for Retinal Disease

UMLS symptoms related to Retinal Disease:


eye manifestations

MGI Mouse Phenotypes related to Retinal Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.09 ABCA4 AIPL1 CACNA1F CEP290 CFH CRB1
2 pigmentation MP:0001186 9.8 ABCA4 BEST1 CEP290 CFH CRB1 CRX
3 vision/eye MP:0005391 9.6 ABCA4 AIPL1 BEST1 CACNA1F CEP290 CFH

Drugs & Therapeutics for Retinal Disease

Drugs for Retinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 869)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
2
Pioglitazone Approved, Investigational Phase 4,Not Applicable 111025-46-8 4829
3
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 347396-82-1 459903
4
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
5
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66635-83-4, 74103-06-3 3826
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 2 13422-55-4
8
Hydroxocobalamin Approved Phase 4,Phase 2,Not Applicable 13422-51-0 11953898 15589840
9
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
10
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
11
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
12
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
13
Nitric Oxide Approved Phase 4,Phase 2,Phase 3 10102-43-9 145068
14
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
15
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2 59-66-5 1986
16
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
19
Dorzolamide Approved Phase 4,Phase 2,Phase 3,Not Applicable 120279-96-1 3154 5284549
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
21
Insulin glargine Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 160337-95-1
22
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
23
Povidone-iodine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 25655-41-8
24
Eplerenone Approved Phase 4,Phase 2,Phase 3,Not Applicable 107724-20-9 150310 443872
25
Temazepam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-50-4 5391
26
Atorvastatin Approved Phase 4,Phase 3,Not Applicable 134523-00-5 60823
27
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
28
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
29
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
30
Povidone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9003-39-8
31
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2 53-86-1 3715
32
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
33
Caffeine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-08-2 2519
34
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
35
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 67-73-2 6215
36
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
37
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
38
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
41
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
42
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
43
Timolol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 26839-75-8 33624 5478
44
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113852-37-2 60613
45
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
46
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
47
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
48
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
49
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63585-09-1, 4428-95-9 3415
50
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454

Interventional clinical trials:

(show top 50) (show all 3304)
# Name Status NCT ID Phase Drugs
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
2 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
3 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
4 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5 Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
6 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
7 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
8 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
10 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
11 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
12 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
13 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
14 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
15 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
16 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
17 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
18 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
19 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
20 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
21 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
22 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
23 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
24 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
25 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
26 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
27 Study of Surgery in Patients With Idiopathic Macular Hole Unknown status NCT02905409 Phase 4
28 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
29 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
30 Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Unknown status NCT02864472 Phase 4 Ranibizumab;ranibizumab PRN
31 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
32 A Study Comparing Efficacy and Safety of "Treat-and-Extend" Regimen Versus PRN of Conbercept in AMD Unknown status NCT02802657 Phase 4 Conbercept
33 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Unknown status NCT02689518 Phase 4 Intravitreal aflibercept injection
34 Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Unknown status NCT01961414 Phase 4 Aflibercept
35 Treatment of AMD With Rheohemapheresis /RHF/ Unknown status NCT01943396 Phase 4
36 Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD Unknown status NCT01213667 Phase 4 Ranibizumab
37 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
38 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
39 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
40 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
41 Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema Unknown status NCT02059772 Phase 4 ranibizumab
42 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
43 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
44 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
45 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
46 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
47 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
48 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
49 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
50 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide

Search NIH Clinical Center for Retinal Disease

Cochrane evidence based reviews: retinal diseases

Genetic Tests for Retinal Disease

Anatomical Context for Retinal Disease

MalaCards organs/tissues related to Retinal Disease:

42
Eye, Endothelial, Retina, Testes, Bone, Brain, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Retinal Disease:

20
The Retina

Publications for Retinal Disease

Articles related to Retinal Disease:

(show top 50) (show all 681)
# Title Authors Year
1
Fate Mapping In Vivo to Distinguish Bona Fide Microglia Versus Recruited Monocyte-Derived Macrophages in Retinal Disease. ( 30324443 )
2019
2
Cell-Based Therapy for Retinal Disease: The New Frontier. ( 30324455 )
2019
3
Correction: Biallelic sequence and structural variants in RAX2 are a novel cause for autosomal recessive inherited retinal disease. ( 30607024 )
2019
4
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease. ( 30617669 )
2019
5
Comparison of repeatability of swept-source and spectral-domain optical coherence tomography for measuring inner retinal thickness in retinal disease. ( 30650130 )
2019
6
Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. ( 30658988 )
2019
7
A nonhuman primate model of inherited retinal disease. ( 30667376 )
2019
8
Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. ( 30711060 )
2019
9
Targeted next generation sequencing reveals genetic defects underlying inherited retinal disease in Iranian families. ( 30820146 )
2019
10
The Role of the Voltage-Gated Potassium Channel Proteins Kv8.2 and Kv2.1 in Vision and Retinal Disease: Insights from the Study of Mouse Gene Knock-Out Mutations. ( 30820446 )
2019
11
Identification and Analysis of Genes Associated with Inherited Retinal Diseases. ( 30324433 )
2019
12
Retinal Fundus Imaging in Mouse Models of Retinal Diseases. ( 30324449 )
2019
13
CRISPR-Cas9 and Its Therapeutic Applications for Retinal Diseases. ( 30585915 )
2019
14
Current Concepts and Emerging Gene Therapies for Inherited Retinal Diseases. ( 30585920 )
2019
15
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. ( 30659496 )
2019
16
Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. ( 30702218 )
2019
17
Micropulse Laser Treatment of Retinal Diseases. ( 30781780 )
2019
18
Progesterone, Lipoic Acid, and Sulforaphane as Promising Antioxidants for Retinal Diseases: A Review. ( 30832304 )
2019
19
Allele frequency analysis of variants reported to cause autosomal dominant inherited retinal diseases question the involvement of 19% of genes and 10% of reported pathogenic variants. ( 30910914 )
2019
20
Autologous stem cell therapy for inherited and acquired retinal disease. ( 29360008 )
2018
21
Expanded Retinal Disease Spectrum Associated With Autosomal Recessive Mutations in GUCY2D. ( 29559409 )
2018
22
Pharmacotherapy of retinal disease with visual cycle modulators. ( 29542350 )
2018
23
Identification of Inherited Retinal Disease-Associated Genetic Variants in 11 Candidate Genes. ( 29320387 )
2018
24
The Role of Microbiota in Retinal Disease. ( 29721973 )
2018
25
Ultra-Widefield Imaging for Pediatric Retinal Disease. ( 29888558 )
2018
26
Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease. ( 29372250 )
2018
27
Special Issue Introduction: Inherited Retinal Disease: Novel Candidate Genes, Genotype-Phenotype Correlations, and Inheritance Models. ( 29659558 )
2018
28
Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. ( 29215958 )
2018
29
Determination of Mitochondrial Oxygen Consumption in the Retina Ex Vivo: Applications for Retinal Disease. ( 29564788 )
2018
30
Basal exon skipping and nonsense-associated altered splicing allows bypassing complete CEP290 loss-of-function in individuals with unusually mild retinal disease. ( 29771326 )
2018
31
Ultra-Widefield Angiography With Oral Fluorescein in Pediatric Patients With Retinal Disease. ( 29621363 )
2018
32
Endoscopy for Pediatric Retinal Disease. ( 29862672 )
2018
33
Retinal findings in a patient of French ancestry with CABP4-related retinal disease. ( 29525873 )
2018
34
Neuroprotective strategies for retinal disease. ( 29481975 )
2018
35
Correspondence between retinotopic cortical mapping and conventional functional and morphological assessment of retinal disease. ( 29699983 )
2018
36
Visual cycle proteins: Structure, function, and roles in human retinal disease. ( 30002120 )
2018
37
The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease. ( 30025106 )
2018
38
Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products. ( 30025989 )
2018
39
Sigma 1 receptor: A novel therapeutic target in retinal disease. ( 30075336 )
2018
40
Clinically applicable deep learning for diagnosis and referral in retinal disease. ( 30104768 )
2018
41
Application of Optical Coherence Tomography Angiography to Retinal Disease. ( 30159165 )
2018
42
The role of OCT-A in retinal disease management. ( 30175386 )
2018
43
Clinical Characterization of 66 Patients With Congenital Retinal Disease Due to the Deep-Intronic c.2991+1655A>G Mutation in CEP290. ( 30193310 )
2018
44
Aqueous flare as a marker of retinal disease activity after anti-VEGF injections. ( 30246338 )
2018
45
The genetics of retinopathy of prematurity: a model for neovascular retinal disease. ( 30250936 )
2018
46
Differences in Static and Kinetic Perimetry Results are Eliminated in Retinal Disease when Psychophysical Procedures are Equated. ( 30280007 )
2018
47
Correction: Mapping the genomic landscape of inherited retinal disease genes prioritizes genes prone to coding and noncoding copy-number variations. ( 30297699 )
2018
48
Gene therapy for RPE65-related retinal disease. ( 30335549 )
2018
49
Progress in Inherited Retinal Disease Drug Discovery and Development: A Foundation's Perspective. ( 30338398 )
2018
50
Research Developments in the Treatment of Retinal Disease: Finalists From the Inaugural Retina Research Scholar Honoree Program. ( 30339261 )
2018

Variations for Retinal Disease

Expression for Retinal Disease

Search GEO for disease gene expression data for Retinal Disease.

Pathways for Retinal Disease

GO Terms for Retinal Disease

Cellular components related to Retinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary basal body GO:0036064 9.5 CEP290 RPGR USH2A
2 photoreceptor disc membrane GO:0097381 9.46 ABCA4 GUCY2D PDE6B RHO
3 photoreceptor connecting cilium GO:0032391 9.43 CEP290 MYO7A USH2A
4 photoreceptor outer segment GO:0001750 9.43 ABCA4 CACNA1F MYO7A PRPH2 RHO RPGR
5 photoreceptor inner segment GO:0001917 9.1 AIPL1 ARMS2 CRB1 MYO7A RHO USH2A

Biological processes related to Retinal Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.83 ABCA4 AIPL1 BEST1 CACNA1F CRX GUCY2D
2 retina development in camera-type eye GO:0060041 9.72 NR2E3 PDE6B PRPH2 RHO RPE65
3 retinoid metabolic process GO:0001523 9.69 ABCA4 RHO RPE65
4 retina homeostasis GO:0001895 9.67 AIPL1 ARMS2 RPE65
5 regulation of rhodopsin mediated signaling pathway GO:0022400 9.67 AIPL1 GUCY2D PDE6B RHO
6 photoreceptor cell maintenance GO:0045494 9.65 ABCA4 RHO USH2A
7 detection of light stimulus involved in visual perception GO:0050908 9.61 BEST1 CACNA1F RPE65
8 sensory perception of light stimulus GO:0050953 9.58 MYO7A RHO USH2A
9 eye photoreceptor cell development GO:0042462 9.56 CEP290 CRB1 MYO7A NR2E3
10 rhodopsin mediated signaling pathway GO:0016056 9.54 PDE6B RHO
11 inner ear receptor cell differentiation GO:0060113 9.52 MYO7A USH2A
12 detection of light stimulus GO:0009583 9.46 PDE6B RHO
13 phototransduction, visible light GO:0007603 9.46 ABCA4 AIPL1 PDE6B RHO
14 response to stimulus GO:0050896 9.44 ABCA4 AIPL1 BEST1 CACNA1F CRX GUCY2D

Sources for Retinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....